Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H (HK:2196)
:2196
2196 Stock Chart & Stats
HK$19.63
-HK$0.04(-0.30%)
At close: 4:00 PM EST
HK$19.63
-HK$0.04(-0.30%)
Day’s Range― - ―
52-Week RangeHK$12.78 - HK$29.00
Previous CloseN/A
Volume1.35M
Average Volume (3M)8.63M
Market Cap
HK$75.74B
Enterprise ValueHK$97.82B
Total Cash (Recent Filing)HK$15.78B
Total Debt (Recent Filing)HK$36.66B
Price to Earnings (P/E)14.2
Beta1.10
Next Earnings
Apr 29, 2026EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend Yield1.69%
Share Statistics
EPS (TTM)0.36
Shares Outstanding551,940,500
10 Day Avg. Volume5,166,409
30 Day Avg. Volume8,626,817
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)0.95
Price to Sales (P/S)1.15
P/FCF Ratio60.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$35.30Price Target Upside79.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.5
Revenue Forecast (FY)HK$43.24B
Bulls Say, Bears Say
Bulls Say
Diversified Healthcare Business ModelFosun Pharma operates across the pharmaceutical value chain—branded/generic drugs, biologics, devices, diagnostics and healthcare services. This vertical and product diversification supports stable revenue streams, cross-selling, and resilience to single-segment shocks over the medium term.
Revenue Recovery To New HighA rebound to record annual revenue in 2025 signals regained commercial traction and market demand for the firm’s products. Sustained top-line growth can enable scale benefits, support R&D investment and improve capacity utilization over the next 2–6 months and beyond.
Healthy Gross Margin ProfileConsistently high gross margins (~48–50%) indicate strong product-level economics and pricing power in core offerings. This margin buffer helps absorb SG&A or R&D spending and supports durable profitability even if operating costs fluctuate in the medium term.
Bears Say
Weak Cash ConversionOperating cash flow is small relative to debt and free cash flow has been historically inconsistent. Low cash conversion reduces the company’s ability to self-fund capex, R&D or debt reduction, increasing reliance on external financing and limiting financial flexibility over the medium term.
Rising LeverageAn increasing debt-to-equity ratio reflects higher leverage as the firm expands. Elevated leverage raises interest and refinancing risk, constrains capital allocation for growth or M&A, and reduces resilience to adverse market or reimbursement shifts over the coming quarters.
Compressed Operating ProfitabilityA meaningful drop in EBIT margin versus prior years suggests margin erosion from higher operating costs, pricing pressure, or mix shifts. Weaker operating profitability limits internal reinvestment and makes earnings growth more sensitive to competitive or cost pressures over time.
Shanghai Fosun Pharmaceutical (Group) Co News
2196 FAQ
What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was HK$12.78 and its highest was HK$29.00 in the past 12 months.
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is HK$75.74B.
When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Apr 29, 2026 which is in 23 days.
How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Mar 24, 2026. The company reported HK$0.364 earnings per share for the quarter, beating the consensus estimate of HK$0.33 by HK$0.034.
Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?
According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Undervalued.
Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pays a Annually dividend of HK$0.35 which represents an annual dividend yield of 1.69%. See more information on Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H dividends here
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.19.
How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.
What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of HK$0.364 in its last earnings report, beating expectations of HK$0.33. Following the earnings report the stock price went up 3.895%.
Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:2196
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.70%
12-Months-Change
Fundamentals
Return on Equity
7.02%
Trailing 12-Months
Asset Growth
6.76%
Trailing 12-Months
Company Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, metabolism, alimentary and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
2196 Stock 12 Month Forecast
Average Price Target
HK$35.30
▲(79.83% Upside)
Technical Analysis
The United Laboratories International Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---